BioXcel Therapeutics
BTAI
41 hedge funds and large institutions have $5.66M invested in BioXcel Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
40% more call options, than puts
Call options by funds: $7K | Put options by funds: $5K
17% more funds holding
Funds holding: 35 → 41 (+6)
1.44% more ownership
Funds ownership: 14.73% → 16.17% (+1.4%)
6% less capital invested
Capital invested by funds: $6.05M → $5.66M (-$389K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.66M |
| 2 |
Jane Street
New York
|
+$263K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$248K |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
+$210K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$290K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$223K |
| 3 |
FIA
Foundations Investment Advisors
Phoenix,
Arizona
|
-$75.6K |
| 4 |
SH
SLT Holdings
Scottsdale,
Arizona
|
-$75.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$24.7K |
BTAI Hedge Fund Activity: Q4 2025 in Review
41 of the 8,230 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2025, worth a combined $5.66M — down 6.4% from $6.05M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BTAI positions and 4 closed out — a net gain of 7 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.66M. The largest seller was XTX Topco, exiting entirely with an estimated $290K sold.
- 41 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2025, up from 35 in Q3 2025.
- Funds reported $5.66M of BioXcel Therapeutics stock for Q4 2025, down 6.4% quarter-over-quarter.
- 11 funds opened new BioXcel Therapeutics positions in Q4 2025 and 4 closed out, a net change of +7 holders.
- The largest BioXcel Therapeutics buyer in Q4 2025 was Millennium Management, an estimated $1.66M added.
- The largest BioXcel Therapeutics seller in Q4 2025 was XTX Topco, an estimated $290K sold.
Based on aggregated 13F filings for Q4 2025.